UROLOGIC CANCER
Clinical trials for UROLOGIC CANCER explained in plain language.
Never miss a new study
Get alerted when new UROLOGIC CANCER trials appear
Sign up with your email to follow new studies for UROLOGIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Bladder cancer drug trial pulled before it started
Disease control TerminatedThis was a planned Phase 3 study to test a drug called NDV-01 (a combination of gemcitabine and docetaxel) in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug, given directly into the bladder, could prevent cancer from coming back …
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Bladder cancer drug trial pulled before it even started
Disease control TerminatedThis study was designed to test a new drug combination (NDV-01) given directly into the bladder for people with a type of early bladder cancer that did not respond to standard BCG treatment. The goal was to see if the drug could make the cancer disappear. However, the trial was w…
Matched conditions: UROLOGIC CANCER
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC